Cytokines as biomarkers of nanoparticle immunotoxicity

Chemical Society Reviews

Volumn 42, Issue 12, 2013, Pages 5552-5576

  Elsabahy, Mahmoud ^a,b   Wooley, Karen L ^a  

^a Department of Electrical and Computer Engineering   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877267968     PISSN: 03060012     EISSN: 14604744     Source Type: Journal    
DOI: 10.1039/c3cs60064e     Document Type: Article

References (204)

1. A. M. Nystrom, K. L. Wooley, The importance of chemistry in creating well-defined nanoscopic embedded therapeutics: devices capable of the dual functions of imaging and therapy, Acc. Chem. Res. 2011, 44, 969-978
2. G. von Maltzahn, J. H. Park, K. Y. Lin, N. Singh, C. Schwoppe, R. Mesters, W. E. Berdel, E. Ruoslahti, M. J. Sailor, S. N. Bhatia, Nanoparticles that communicate in vivo to amplify tumour targeting, Nat. Mater. 2011, 10, 545-552
3. J. W. Yoo, D. J. Irvine, D. E. Discher, S. Mitragotri, Bio-inspired, bioengineered and biomimetic drug delivery carriers, Nat. Rev. Drug Discovery, 2011, 10, 521-535
4. M. Elsabahy, K. L. Wooley, Design of polymeric nanoparticles for biomedical delivery applications, Chem. Soc. Rev. 2012, 41, 2545-2561
5. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 2010, 464, 1067-1070
6. K. Zhang, H. Fang, Z. Wang, Z. Li, J. S. Taylor, K. L. Wooley, Structure-activity relationships of cationic shell-crosslinked knedel-like nanoparticles: shell composition and transfection efficiency/cytotoxicity, Biomaterials, 2010, 31, 1805-1813
7. K. Zhang, H. Fang, G. Shen, J. S. Taylor, K. L. Wooley, Well-defined cationic shell crosslinked nanoparticles for efficient delivery of DNA or peptide nucleic acids, Proc. Am. Thorac. Soc. 2009, 6, 450-457
8. P. J. Tacken, I. S. Zeelenberg, L. J. Cruz, M. A. van Hout-Kuijer, G. van de Glind, R. G. Fokkink, A. J. Lambeck, C. G. Figdor, Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity, Blood, 2011, 118, 6836-6844
9. M. Elsabahy, M. H. Dufresne and J. C. Leroux, in Materials for Nanomedicine, ed. V. Torchilin and M. Amiji, Pan Stanford Publishing, Hackensack, 2010, pp. 169–234
10. M. A. Dobrovolskaia, S. E. McNeil, Immunological properties of engineered nanomaterials, Nat. Nanotechnol. 2007, 2, 469-478
11. B. S. Zolnik, A. Gonzalez-Fernandez, N. Sadrieh, M. A. Dobrovolskaia, Nanoparticles and the immune system, Endocrinology, 2010, 151, 458-465
12. S. Hussain, J. A. Vanoirbeek, P. H. Hoet, Interactions of nanomaterials with the immune system, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2011, 4, 169-183
13. M. A. Dobrovolskaia, D. R. Germolec, J. L. Weaver, Evaluation of nanoparticle immunotoxicity, Nat. Nanotechnol. 2009, 4, 411-414
14. P. D. Dwivedi, A. Tripathi, K. M. Ansari, R. Shanker, M. Das, Impact of nanoparticles on the immune system, J. Biomed. Nanotechnol. 2011, 7, 193-194
15. C. Chang, The immune effects of naturally occurring and synthetic nanoparticles, J. Autoimmun. 2010, 34, J234-J246
16. S. Breslin, Cytokine-release syndrome: overview and nursing implications, Clin. J. Oncol. Nurs. 2007, 11, 37-42
17. C. K. Schneider, U. Kalinke, J. Lower, TGN1412 – a regulator's perspective, Nat. Biotechnol. 2006, 24, 493-496
18. P. Rajananthanan, G. S. Attard, N. A. Sheikh, W. J. Morrow, Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice, Vaccine, 1999, 18, 140-152
19. C. A. Black, Delayed type hypersensitivity: current theories with an historic perspective, Dermatol. Online J. 1999, 5, 7
20. C. S. Ma, S. G. Tangye, E. K. Deenick, Human Th9 cells: inflammatory cytokines modulate IL-9 production through the induction of IL-21, Immunol. Cell Biol. 2010, 88, 621-623
21. R. Medzhitov, E. M. Shevach, G. Trinchieri, A. L. Mellor, D. H. Munn, S. Gordon, P. Libby, G. K. Hansson, K. Shortman, C. Dong, D. Gabrilovich, L. Gabrysova, A. Howes, A. O'Garra, Highlights of 10 years of immunology in Nature Reviews Immunology, Nat. Rev. Immunol. 2011, 11, 693-702
22. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, R. L. Coffman, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, 1986, J. Immunol. 2005, 175, 5-14
23. J. Wang, B. Chen, N. Jin, G. Xia, Y. Chen, Y. Zhou, X. Cai, J. Ding, X. Li, X. Wang, The changes of T lymphocytes and cytokines in ICR mice fed with Fe magnetic nanoparticles, Int. J. Nanomed. 2011, 6, 605-610
24. H. Kokkonen, I. Soderstrom, J. Rocklov, G. Hallmans, K. Lejon, S. R. Dahlqvist, Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis, Arthritis Rheum. 2010, 62, 383-391
25. T. H. Nguyen, T. B. Casale, Immune modulation for treatment of allergic disease, Immunol. Rev. 2011, 242, 258-271
26. P. Kidd, Th1/Th2 balance: the hypothesis, its limitations and implications for health and disease, Altern. Med. Rev. 2003, 8, 223-246
27. Q. Lan, S. S. Wang, I. Menashe, B. Armstrong, Y. Zhang, P. Hartge, M. P. Purdue, T. R. Holford, L. M. Morton, A. Kricker, J. R. Cerhan, A. Grulich, W. Cozen, S. H. Zahm, M. Yeager, C. M. Vajdic, M. Schenk, B. Leaderer, J. Yuenger, R. K. Severson, N. Chatterjee, S. J. Chanock, T. Zheng, N. Rothman, Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies, Br. J. Haematol. 2011, 153, 341-350
28. M. F. Neurath, S. Finotto, L. H. Glimcher, The role of Th1/Th2 polarization in mucosal immunity, Nat. Med. 2002, 8, 567-573
29. E. Benjamini, R. Coico and G. Sunshine, in Immunology, ed. D. H. Margulies, John Wiley and Sons, Inc. New York, 2000
30. L. W. Zhang, W. W. Yu, V. L. Colvin, N. A. Monteiro-Riviere, Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes, Toxicol. Appl. Pharmacol. 2008, 228, 200-211
31. J. P. Ryman-Rasmussen, J. E. Riviere, N. A. Monteiro-Riviere, Surface coatings determine cytotoxicity and irritation potential of quantum dot nanoparticles in epidermal keratinocytes, J. Invest. Dermatol. 2007, 127, 143-153
32. B. H. Kim, Y. S. Lee, K. S. Kang, The mechanism of retinol-induced irritation and its application to anti-irritant development, Toxicol. Lett. 2003, 146, 65-73
33. A. Grone, Keratinocytes and cytokines, Vet. Immunol. Immunopathol. 2002, 88, 1-12
34. A. Beyerle, M. Irmler, J. Beckers, T. Kissel, T. Stoeger, Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications, Mol. Pharmaceutics, 2010, 7, 727-737
35. M. R. Powers, M. H. Davies, J. P. Eubanks, Increased expression of chemokine KC, an interleukin-8 homologue, in a model of oxygen-induced retinopathy, Curr. Eye Res. 2005, 30, 299-307
36. J. R. Cubillos-Ruiz, X. Engle, U. K. Scarlett, D. Martinez, A. Barber, R. Elgueta, L. Wang, Y. Nesbeth, Y. Durant, A. T. Gewirtz, C. L. Sentman, R. Kedl, J. R. Conejo-Garcia, Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, J. Clin. Invest. 2009, 119, 2231-2244
37. L. Lanier, in Basic human immunology, ed. D. P. Stites and A. I. Terr, Appleton and Lange, Norwalk, CA, 1991
38. A. E. Felber, M. H. Dufresne, J. C. Leroux, pH-sensitive vesicles, polymeric micelles and nanospheres prepared with polycarboxylates, Adv. Drug Delivery Rev. 2010, 64, 979-992
39. B. Y. Kim, J. T. Rutka, W. C. Chan, Nanomedicine, N. Engl. J. Med. 2010, 363, 2434-2443
40. R. A. Petros, J. M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discovery, 2010, 9, 615-627
41. J. Shi, Z. Xiao, N. Kamaly, O. C. Farokhzad, Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation, Acc. Chem. Res. 2011, 44, 1123-1134
42. K. K. Jain, Advances in the field of nanooncology, BMC Med. 2010, 8, 83
43. S. C. Hyde, I. A. Pringle, S. Abdullah, A. E. Lawton, L. A. Davies, A. Varathalingam, G. Nunez-Alonso, A. M. Green, R. P. Bazzani, S. G. Sumner-Jones, M. Chan, H. Li, N. S. Yew, S. H. Cheng, A. C. Boyd, J. C. Davies, U. Griesenbach, D. J. Porteous, D. N. Sheppard, F. M. Munkonge, E. W. Alton, D. R. Gill, CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression, Nat. Biotechnol. 2008, 26, 549-551
44. Y. Tan, S. Li, B. R. Pitt, L. Huang, The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo, Hum. Gene Ther. 1999, 10, 2153-2161
45. J. W. Singer, Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane, J. Controlled Release, 2005, 109, 120-126
46. J. W. Singer, S. Shaffer, B. Baker, A. Bernareggi, S. Stromatt, D. Nienstedt, M. Besman, Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane, Anticancer Drugs, 2005, 16, 243-254
47. L. R. Stanberry, J. K. Simon, C. Johnson, P. L. Robinson, J. Morry, M. R. Flack, S. Gracon, A. Myc, T. Hamouda, J. R. Baker, Jr. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W(80)5EC combined with approved seasonal influenza antigens, Vaccine, 2012, 30, 307-316
48. A. Gianella, P. A. Jarzyna, V. Mani, S. Ramachandran, C. Calcagno, J. Tang, B. Kann, W. J. Dijk, V. L. Thijssen, A. W. Griffioen, G. Storm, Z. A. Fayad, W. J. Mulder, Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer, ACS Nano, 2011, 5, 4422-4433
49. K. Kataoka, A. Harada, Y. Nagasaki, Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv. Drug Delivery Rev. 2001, 47, 113-131
50. V. P. Torchilin, Micellar nanocarriers: pharmaceutical perspectives, Pharm. Res. 2007, 24, 1-16
51. G. Gaucher, M. H. Dufresne, V. P. Sant, N. Kang, D. Maysinger, J. C. Leroux, Block copolymer micelles: preparation, characterization and application in drug delivery, J. Controlled Release, 2005, 109, 169-188
52. M. Elsabahy, K. L. Wooley, Strategies toward well-defined polymer nanoparticles inspired by nature: chemistry versus versatility, J. Polym. Sci. Part A: Polym. Chem. 2012, 50, 1869-1880
53. K. Fuhrmann, J. D. Schulz, M. A. Gauthier, J. C. Leroux, PEG Nanocages as non-sheddable stabilizers for drug nanocrystals, ACS Nano, 2012, 6, 1667-1676
54. M. J. Hawkins, P. Soon-Shiong, N. Desai, Protein nanoparticles as drug carriers in clinical medicine, Adv. Drug Delivery Rev. 2008, 60, 876-885
55. C. Li, S. Wallace, Polymer-drug conjugates: recent development in clinical oncology, Adv. Drug Delivery Rev. 2008, 60, 886-898
56. C. Wolfrum, S. Shi, K. N. Jayaprakash, M. Jayaraman, G. Wang, R. K. Pandey, K. G. Rajeev, T. Nakayama, K. Charrise, E. M. Ndungo, T. Zimmermann, V. Koteliansky, M. Manoharan, M. Stoffel, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat. Biotechnol. 2007, 25, 1149-1157
57. P. Simard, J. C. Leroux, In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen, Mol. Pharmaceutics, 2010, 7, 1098-1107
58. S. Movassaghian, H. R. Moghimi, F. H. Shirazi, V. P. Torchilin, Dendrosome-dendriplex inside liposomes: as a gene delivery system, J. Drug Targeting, 2011, 19, 925-932
59. D. Bedi, T. Musacchio, O. A. Fagbohun, J. W. Gillespie, P. Deinnocentes, R. C. Bird, L. Bookbinder, V. P. Torchilin, V. A. Petrenko, Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes, Nanomedicine, 2011, 7, 315-323
60. N. Nishiyama, K. Kataoka, Current state, achievements and future prospects of polymeric micelles as nanocarriers for drug and gene delivery, Pharmacol. Ther. 2006, 112, 630-648
61. J. A. Wolff, D. B. Rozema, Breaking the bonds: non-viral vectors become chemically dynamic, Mol. Ther. 2008, 16, 8-15
62. M. Elsabahy, N. Wazen, N. Puxan, G. Deleavey, M. Servant, M. J. Damha, J. C. Leroux, Delivery of nucleic acids through the controlled disassembly of multifunctional nanocomplexes, Adv. Funct. Mater. 2009, 19, 3862-3867
63. S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley, E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. L. Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. Chen, R. Alvarez, S. A. Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. Manoharan, M. A. Ciufolini, M. A. Tracy, A. de Fougerolles, I. MacLachlan, P. R. Cullis, T. D. Madden, M. J. Hope, Rational design of cationic lipids for siRNA delivery, Nat. Biotechnol. 2010, 28, 172-176
64. A. D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, I. MacLachlan, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice, J. Clin. Invest. 2009, 119, 661-673
65. E. C. Dreaden, M. A. Mackey, X. Huang, B. Kang, M. A. El-Sayed, Beating cancer in multiple ways using nanogold, Chem. Soc. Rev. 2011, 40, 3391-3404
66. J. H. Lee, K. Lee, S. H. Moon, Y. Lee, T. G. Park, J. Cheon, All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery, Angew. Chem. Int. Ed. 2009, 48, 4174-4179
67. H. C. Huang, S. Barua, G. Sharma, S. K. Dey, K. Rege, Inorganic nanoparticles for cancer imaging and therapy, J. Controlled Release, 2011, 155, 344-357
68. M. Prato, K. Kostarelos, A. Bianco, Functionalized carbon nanotubes in drug design and discovery, Acc. Chem. Res. 2008, 41, 60-68
69. Z. Liu, C. Davis, W. Cai, L. He, X. Chen, H. Dai, Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy, Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 1410-1415
70. K. Hattori, M. Nishikawa, K. Watcharanurak, A. Ikoma, K. Kabashima, H. Toyota, Y. Takahashi, R. Takahashi, Y. Watanabe, Y. Takakura, Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization, J. Immunol. 2010, 184, 2729-2735
71. Y. Liu, F. Jiao, Y. Qiu, W. Li, F. Lao, G. Zhou, B. Sun, G. Xing, J. Dong, Y. Zhao, Z. Chai, C. Chen, The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity, Biomaterials, 2009, 30, 3934-3945
72. D. Mohanan, B. Slutter, M. Henriksen-Lacey, W. Jiskoot, J. A. Bouwstra, Y. Perrie, T. M. Kundig, B. Gander, P. Johansen, Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems, J. Controlled Release, 2010, 147, 342-349
73. B. C. Schanen, A. S. Karakoti, S. Seal, D. R. Drake, W. L. Warren, W. T. Self, Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct, ACS Nano, 2009, 3, 2523-2532
74. M. Ghoneum, A. Ghoneum, J. Gimzewski, Nanodiamond and nanoplatinum liquid, DPV576, activates human monocyte-derived dendritic cells in vitro, Anticancer Res. 2010, 30, 4075-4079
75. B. Sun, X. Wang, Z. Ji, R. Li, T. Xia, NLRP3 Inflammasome Activation Induced by Engineered Nanomaterials, Small, 2012, DOI: 10.1002/smll.201201962
76. E. J. Yang, S. Kim, J. S. Kim, I. H. Choi, Inflammasome formation and IL-1beta release by human blood monocytes in response to silver nanoparticles, Biomaterials, 2012, 33, 6858-6867
77. W. J. Sandberg, M. Lag, J. A. Holme, B. Friede, M. Gualtieri, M. Kruszewski, P. E. Schwarze, T. Skuland, M. Refsnes, Comparison of non-crystalline silica nanoparticles in IL-1beta release from macrophages, Part. Fibre Toxicol. 2012, 9, 32
78. E. Meunier, A. Coste, D. Olagnier, H. Authier, L. Lefevre, C. Dardenne, J. Bernad, M. Beraud, E. Flahaut, B. Pipy, Double-walled carbon nanotubes trigger IL-1beta release in human monocytes through Nlrp3 inflammasome activation, Nanomedicine, 2012, 8, 987-995
79. M. A. Conway, L. Madrigal-Estebas, S. McClean, D. J. Brayden, K. H. Mills, Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells, Vaccine, 2001, 19, 1940-1950
80. M. A. Dobrovolskaia, P. Aggarwal, J. B. Hall, S. E. McNeil, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution, Mol. Pharmaceutics, 2008, 5, 487-495
81. P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, S. E. McNeil, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv. Drug Delivery Rev. 2009, 61, 428-437
82. S. T. Reddy, A. J. van der Vlies, E. Simeoni, V. Angeli, G. J. Randolph, C. P. O'Neil, L. K. Lee, M. A. Swartz, J. A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol. 2007, 25, 1159-1164
83. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, M. F. Bachmann, Nanoparticles target distinct dendritic cell populations according to their size, Eur. J. Immunol. 2008, 38, 1404-1413
84. S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, A. Lavasanifar, Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity, Vaccine, 2008, 26, 5046-5057
85. J. Singh, S. Pandit, V. W. Bramwell, H. O. Alpar, Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems, Methods, 2006, 38, 96-105
86. C. Thomas, A. Rawat, L. Hope-Weeks, F. Ahsan, Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine, Mol. Pharmaceutics, 2011, 8, 405-415
87. M. Kumar, X. Kong, A. K. Behera, G. R. Hellermann, R. F. Lockey, S. S. Mohapatra, Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma, Genet. Vaccines Ther. 2003, 1, 3
88. H. F. Florindo, S. Pandit, L. M. Goncalves, H. O. Alpar, A. J. Almeida, New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model, Vaccine, 2009, 27, 1230-1241
89. Y. Morikawa, M. Furotani, N. Matsuura, K. Kakudo, The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. II. Epidermal Langerhans' cells and peritoneal exudate macrophages, Cell. Immunol. 1993, 152, 200-210
90. T. F. Gajewski, M. Pinnas, T. Wong, F. W. Fitch, Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations, J. Immunol. 1991, 146, 1750-1758
91. T. Liu, L. Li, C. Fu, H. Liu, D. Chen, F. Tang, Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles, Biomaterials, 2012, 33, 2399-2407
92. C. Moon, H. J. Park, Y. H. Choi, E. M. Park, V. Castranova, J. L. Kang, Pulmonary inflammation after intraperitoneal administration of ultrafine titanium dioxide at rest or in lungs primed with lipopolysaccharide, J. Toxicol. Environ. Health, Part A, 2010, 73, 396-409
93. J. A. Shin, E. J. Lee, S. M. Seo, H. S. Kim, J. L. Kang, E. M. Park, Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse, Neuroscience, 2010, 165, 445-454
94. S. T. Larsen, M. Roursgaard, K. A. Jensen, G. D. Nielsen, Nano titanium dioxide particles promote allergic sensitization and lung inflammation in mice, Basic Clin. Pharmacol. Toxicol. 2010, 106, 114-117
95. N. Tsao, P. P. Kanakamma, T. Y. Luh, C. K. Chou, H. Y. Lei, Inhibition of Escherichia coli-induced meningitis by carboxyfullerence, Antimicrob. Agents Chemother. 1999, 43, 2273-2277
96. A. Nazmi, K. Dutta, A. Basu, Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis, PLoS Neglected Trop. Dis. 2010, 4, e892
97. D. Doroud, F. Zahedifard, A. Vatanara, A. R. Najafabadi, S. Rafati, Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice, Parasite Immunol. 2011, 33, 335-348
98. A. Aderem, D. M. Underhill, Mechanisms of phagocytosis in macrophages, Annu. Rev. Immunol. 1999, 17, 593-623
99. A. Iwasaki, R. Medzhitov, Toll-like receptor control of the adaptive immune responses, Nat. Immunol. 2004, 5, 987-995
100. C. Pasare, R. Medzhitov, Toll-like receptors: linking innate and adaptive immunity, Adv. Exp. Med. Biol. 2005, 560, 11-18
101. W. Tao, X. Mao, J. P. Davide, B. Ng, M. Cai, P. A. Burke, A. B. Sachs, L. Sepp-Lorenzino, Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses, Mol. Ther. 2011, 19, 567-575
102. K. R. Bortoluci, R. Medzhitov, Control of infection by pyroptosis and autophagy: role of TLR and NLR, Cell. Mol. Life Sci. 2010, 67, 1643-1651
103. C. Van Waes, Nuclear factor-kappaB in development, prevention and therapy of cancer, Clin. Cancer Res. 2007, 13, 1076-1082
104. T. H. Kim, J. W. Nah, M. H. Cho, T. G. Park, C. S. Cho, Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles, J. Nanosci. Nanotechnol. 2006, 6, 2796-2803
105. A. V. Chavez-Santoscoy, R. Roychoudhury, N. L. Pohl, M. J. Wannemuehler, B. Narasimhan, A. E. Ramer-Tait, Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using “pathogen-like” amphiphilic polyanhydride nanoparticles, Biomaterials, 2012, 33, 4762-4772
106. B. Carrillo-Conde, E. H. Song, A. Chavez-Santoscoy, Y. Phanse, A. E. Ramer-Tait, N. L. Pohl, M. J. Wannemuehler, B. H. Bellaire, B. Narasimhan, Mannose-functionalized “pathogen-like” polyanhydride nanoparticles target C-type lectin receptors on dendritic cells, Mol. Pharmaceutics, 2011, 8, 1877-1886
107. S. Hamdy, A. Haddadi, V. Somayaji, D. Ruan, J. Samuel, Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (dl-lactic-co-glycolic acid) nanoparticle formulations, J. Pharm. Biomed. Anal. 2007, 44, 914-923
108. Z. J. Deng, M. Liang, M. Monteiro, I. Toth, R. F. Minchin, Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation, Nat. Nanotechnol. 2011, 6, 39-44
109. Z. Cui, S. J. Han, D. P. Vangasseri, L. Huang, Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier, Mol. Pharmaceutics, 2005, 2, 22-28
110. B. C. Heng, X. Zhao, E. C. Tan, N. Khamis, A. Assodani, S. Xiong, C. Ruedl, K. W. Ng, J. S. Loo, Evaluation of the cytotoxic and inflammatory potential of differentially shaped zinc oxide nanoparticles, Arch. Toxicol. 2011, 85, 1517-1528
111. T. G. Iversena, T. Skotlanda, K. Sandvig, Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies, Nano Today, 2011, 6, 176-185
112. S. Hussain, S. Boland, A. Baeza-Squiban, R. Hamel, L. C. Thomassen, J. A. Martens, M. A. Billon-Galland, J. Fleury-Feith, F. Moisan, J. C. Pairon, F. Marano, Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount, Toxicology, 2009, 260, 142-149
113. L. C. Renwick, D. Brown, A. Clouter, K. Donaldson, Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types, Occup. Environ. Med. 2004, 61, 442-447
114. A. Nel, T. Xia, L. Madler, N. Li, Toxic potential of materials at the nanolevel, Science, 2006, 311, 622-627
115. G. Oberdorster, E. Oberdorster, J. Oberdorster, Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles, Environ. Health Perspect. 2005, 113, 823-839
116. C. Monteiller, L. Tran, W. MacNee, S. Faux, A. Jones, B. Miller, K. Donaldson, The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area, Occup. Environ. Med. 2007, 64, 609-615
117. S. Singh, T. Shi, R. Duffin, C. Albrecht, D. van Berlo, D. Hohr, B. Fubini, G. Martra, I. Fenoglio, P. J. Borm, R. P. Schins, Endocytosis, oxidative stress and IL-8 expression in human lung epithelial cells upon treatment with fine and ultrafine TiO ole of the specific surface area and of surface methylation of the particles, Toxicol. Appl. Pharmacol. 2007, 222, 141-151
118. K. Wittmaack, In search of the most relevant parameter for quantifying lung inflammatory response to nanoparticle exposure: particle number, surface area, or what?, Environ. Health Perspect. 2007, 115, 187-194
119. D. B. Warheit, T. R. Webb, C. M. Sayes, V. L. Colvin, K. L. Reed, Pulmonary instillation studies with nanoscale TiO rods and dots in rats: toxicity is not dependent upon particle size and surface area, Toxicol. Sci. 2006, 91, 227-236
120. L. Rettig, S. P. Haen, A. G. Bittermann, L. von Boehmer, A. Curioni, S. D. Kramer, A. Knuth, S. Pascolo, Particle size and activation threshold: a new dimension of danger signaling, Blood, 2010, 115, 4533-4541
121. G. Minigo, A. Scholzen, C. K. Tang, J. C. Hanley, M. Kalkanidis, G. A. Pietersz, V. Apostolopoulos, M. Plebanski, Poly-l-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy, Vaccine, 2007, 25, 1316-1327
122. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram, I. F. McKenzie, M. Plebanski, Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors, J. Immunol. 2004, 173, 3148-3154
123. P. L. Mottram, D. Leong, B. Crimeen-Irwin, S. Gloster, S. D. Xiang, J. Meanger, R. Ghildyal, N. Vardaxis, M. Plebanski, Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus, Mol. Pharmaceutics, 2007, 4, 73-84
124. J. Kreuter, E. Liehl, U. Berg, M. Soliva, P. P. Speiser, Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants, Vaccine, 1988, 6, 253-256
125. T. Morishige, Y. Yoshioka, H. Inakura, A. Tanabe, S. Narimatsu, X. Yao, Y. Monobe, T. Imazawa, S. Tsunoda, Y. Tsutsumi, Y. Mukai, N. Okada, S. Nakagawa, Suppression of nanosilica particle-induced inflammation by surface modification of the particles, Arch. Toxicol. 2012, 86, 1297-1307
126. R. Shrestha, M. Elsabahy, S. Florez-Malaver, S. Samarajeewa, K. L. Wooley, Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities, Biomaterials, 2012, 33, 8557-8568
127. H. Yoshida, M. Nishikawa, S. Yasuda, Y. Mizuno, H. Toyota, T. Kiyota, R. Takahashi, Y. Takakura, TLR9-dependent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice, J. Gene Med. 2009, 11, 708-717
128. D. Rottembourg, C. M. Filippi, D. Bresson, K. Ehrhardt, E. A. Estes, J. E. Oldham, M. G. von Herrath, Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection, J. Immunol. 2010, 184, 7100-7107
129. K. Kariko, P. Bhuyan, J. Capodici, D. Weissman, Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3, J. Immunol. 2004, 172, 6545-6549
130. E. W. Alton, M. Stern, R. Farley, A. Jaffe, S. L. Chadwick, J. Phillips, J. Davies, S. N. Smith, J. Browning, M. G. Davies, M. E. Hodson, S. R. Durham, D. Li, P. K. Jeffery, M. Scallan, R. Balfour, S. J. Eastman, S. H. Cheng, A. E. Smith, D. Meeker, D. M. Geddes, Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial, Lancet, 1999, 353, 947-954
131. F. E. Ruiz, J. P. Clancy, M. A. Perricone, Z. Bebok, J. S. Hong, S. H. Cheng, D. P. Meeker, K. R. Young, R. A. Schoumacher, M. R. Weatherly, L. Wing, J. E. Morris, L. Sindel, M. Rosenberg, F. W. van Ginkel, J. R. McGhee, D. Kelly, R. K. Lyrene, E. J. Sorscher, A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis, Hum. Gene Ther. 2001, 12, 751-761
132. B. D. Freimark, H. P. Blezinger, V. J. Florack, J. L. Nordstrom, S. D. Long, D. S. Deshpande, S. Nochumson, K. L. Petrak, Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes, J. Immunol. 1998, 160, 4580-4586
133. R. K. Scheule, J. A. St George, R. G. Bagley, J. Marshall, J. M. Kaplan, G. Y. Akita, K. X. Wang, E. R. Lee, D. J. Harris, C. Jiang, N. S. Yew, A. E. Smith, S. H. Cheng, Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung, Hum. Gene Ther. 1997, 8, 689-707
134. N. S. Yew, K. X. Wang, M. Przybylska, R. G. Bagley, M. Stedman, J. Marshall, R. K. Scheule, S. H. Cheng, Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes, Hum. Gene Ther. 1999, 10, 223-234
135. A. Goodchild, N. Nopper, A. King, T. Doan, M. Tanudji, G. M. Arndt, M. Poidinger, L. P. Rivory, T. Passioura, Sequence determinants of innate immune activation by short interfering RNAs, BMC Immunol. 2009, 10, 40
136. M. Sioud, RNA interference and innate immunity, Adv. Drug Delivery Rev. 2007, 59, 153-163
137. A. Judge, I. MacLachlan, Overcoming the innate immune response to small interfering RNA, Hum. Gene Ther. 2008, 19, 111-124
138. D. V. Morrissey, J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C. S. Shaffer, L. B. Jeffs, A. Judge, I. MacLachlan, B. Polisky, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, Nat. Biotechnol. 2005, 23, 1002-1007
139. J. Y. Kim, S. Choung, E. J. Lee, Y. J. Kim, Y. C. Choi, Immune activation by siRNA/liposome complexes in mice is sequence-independent: lack of a role for Toll-like receptor 3 signaling, Mol. Cells, 2007, 24, 247-254
140. A. D. Judge, G. Bola, A. C. Lee, I. MacLachlan, Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo, Mol. Ther. 2006, 13, 494-505
141. L. Sepp-Lorenzino, M. Ruddy, Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides, Clin. Pharmacol. Ther. 2008, 84, 628-632
142. M. T. Abrams, M. L. Koser, J. Seitzer, S. C. Williams, M. A. DiPietro, W. Wang, A. W. Shaw, X. Mao, V. Jadhav, J. P. Davide, P. A. Burke, A. B. Sachs, S. M. Stirdivant, L. Sepp-Lorenzino, Evaluation of efficacy, biodistribution and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment, Mol. Ther. 2010, 18, 171-180
143. T. S. Zimmermann, A. C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M. N. Fedoruk, J. Harborth, J. A. Heyes, L. B. Jeffs, M. John, A. D. Judge, K. Lam, K. McClintock, L. V. Nechev, L. R. Palmer, T. Racie, I. Rohl, S. Seiffert, S. Shanmugam, V. Sood, J. Soutschek, I. Toudjarska, A. J. Wheat, E. Yaworski, W. Zedalis, V. Koteliansky, M. Manoharan, H. P. Vornlocher, I. MacLachlan, RNAi-mediated gene silencing in non-human primates, Nature, 2006, 441, 111-114
144. A. D. Judge, V. Sood, J. R. Shaw, D. Fang, K. McClintock, I. MacLachlan, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, Nat. Biotechnol. 2005, 23, 457-462
145. L. Zitvogel, L. Apetoh, F. Ghiringhelli, G. Kroemer, Immunological aspects of cancer chemotherapy, Nat. Rev. Immunol. 2008, 8, 59-73
146. T. K. Yeung, C. Germond, X. Chen, Z. Wang, The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration, Biochem. Biophys. Res. Commun. 1999, 263, 398-404
147. A. Javeed, M. Ashraf, A. Riaz, A. Ghafoor, S. Afzal, M. M. Mukhtar, Paclitaxel and immune system, Eur. J. Pharm. Sci. 2009, 38, 283-290
148. C. A. Byrd-Leifer, E. F. Block, K. Takeda, S. Akira, A. Ding, The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol, Eur. J. Immunol. 2001, 31, 2448-2457
149. O. T. Chan, L. X. Yang, The immunological effects of taxanes, Cancer Immunol. Immunother. 2000, 49, 181-185
150. R. Stebbings, L. Findlay, C. Edwards, D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, B. Fox, G. Tarrant, J. Robinson, T. Meager, C. Dolman, S. J. Thorpe, A. Bristow, M. Wadhwa, R. Thorpe, S. Poole, “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J. Immunol. 2007, 179, 3325-3331
151. G. Suntharalingam, M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N. Engl. J. Med. 2006, 355, 1018-1028
152. C. F. Jones, D. W. Grainger, In vitro assessments of nanomaterial toxicity, Adv. Drug Delivery Rev. 2009, 61, 438-456
153. H. Vallhov, J. Qin, S. M. Johansson, N. Ahlborg, M. A. Muhammed, A. Scheynius, S. Gabrielsson, The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications, Nano Lett. 2006, 6, 1682-1686
154. M. A. Dobrovolskaia, B. W. Neun, J. D. Clogston, H. Ding, J. Ljubimova, S. E. McNeil, Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations, Nanomedicine, 2010, 5, 555-562
155. A. C. Reisetter, L. V. Stebounova, J. Baltrusaitis, L. Powers, A. Gupta, V. H. Grassian, M. M. Monick, Induction of inflammasome-dependent pyroptosis by carbon black nanoparticles, J. Biol. Chem. 2011, 286, 21844-21852
156. R. F. Hamilton, N. Wu, D. Porter, M. Buford, M. Wolfarth, A. Holian, Particle length-dependent titanium dioxide nanomaterials toxicity and bioactivity, Part. Fibre Toxicol. 2009, 6, 35
157. K. Inoue, H. Takano, Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation, Sci. World J. 2011, 11, 382-390
158. K. Inoue, H. Takano, R. Yanagisawa, S. Hirano, T. Kobayashi, Y. Fujitani, A. Shimada, T. Yoshikawa, Effects of inhaled nanoparticles on acute lung injury induced by lipopolysaccharide in mice, Toxicology, 2007, 238, 99-110
159. K. Inoue, H. Takano, R. Yanagisawa, S. Hirano, M. Sakurai, A. Shimada, T. Yoshikawa, Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice, Environ. Health Perspect. 2006, 114, 1325-1330
160. Y. Shi, S. Yadav, F. Wang, H. Wang, Endotoxin promotes adverse effects of amorphous silica nanoparticles on lung epithelial cells in vitro, J. Toxicol. Environ. Health, Part A, 2010, 73, 748-756
161. A. A. Shvedova, E. R. Kisin, R. Mercer, A. R. Murray, V. J. Johnson, A. I. Potapovich, Y. Y. Tyurina, O. Gorelik, S. Arepalli, D. Schwegler-Berry, A. F. Hubbs, J. Antonini, D. E. Evans, B. K. Ku, D. Ramsey, A. Maynard, V. E. Kagan, V. Castranova, P. Baron, Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice, Am. J. Physiol.: Lung Cell. Mol. Physiol. 2005, 289, L698-L708
162. A. R. Murray, E. Kisin, S. S. Leonard, S. H. Young, C. Kommineni, V. E. Kagan, V. Castranova, A. A. Shvedova, Oxidative stress and inflammatory response in dermal toxicity of single-walled carbon nanotubes, Toxicology, 2009, 257, 161-171
163. K. Pulskamp, S. Diabate, H. F. Krug, Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants, Toxicol. Lett. 2007, 168, 58-74
164. T. Lawrence, The nuclear factor NF-kappaB pathway in inflammation, Cold Spring Harbor Perspect. Biol. 2009, 1, a001651
165. T. Kawai, S. Akira, Signaling to NF-kappaB by Toll-like receptors, Trends Mol. Med. 2007, 13, 460-469
166. T. S. Blackwell, J. W. Christman, The role of nuclear factor-kappa B in cytokine gene regulation, Am. J. Respir. Cell. Mol. Biol. 1997, 17, 3-9
167. K. Takeda, T. Kaisho, S. Akira, Toll-like receptors, Annu. Rev. Immunol. 2003, 21, 335-376
168. E. F. Morand, Effects of glucocorticoids on inflammation and arthritis, Curr. Opin. Rheumatol. 2007, 19, 302-307
169. P. N. Moynagh, Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids, J. Endocrinol. 2003, 179, 139-144
170. S. Val, S. Hussain, S. Boland, R. Hamel, A. Baeza-Squiban, F. Marano, Carbon black and titanium dioxide nanoparticles induce pro-inflammatory responses in bronchial epithelial cells: need for multiparametric evaluation due to adsorption artifacts, Inhalation Toxicol. 2009, 21, 115-122
171. F. A. Witzmann, N. A. Monteiro-Riviere, Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes, Nanomedicine, 2006, 2, 158-168
172. C. A. Poland, R. Duffin, I. Kinloch, A. Maynard, W. A. Wallace, A. Seaton, V. Stone, S. Brown, W. Macnee, K. Donaldson, Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study, Nat. Nanotechnol. 2008, 3, 423-428
173. A. Batista-Duharte, E. B. Lindblad, E. Oviedo-Orta, Progress in understanding adjuvant immunotoxicity mechanisms, Toxicol. Lett. 2011, 203, 97-105
174. I. H. Khan, V. V. Krishnan, M. Ziman, K. Janatpour, T. Wun, P. A. Luciw, J. Tuscano, A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients, Cytometry, Part B, 2009, 76, 159-168
175. T. Shiraki, E. Takayama, H. Magari, T. Nakata, T. Maekita, S. Enomoto, Y. Mori, N. Shingaki, K. Moribata, H. Deguchi, K. Ueda, I. Inoue, M. Mizuno-Kamiya, K. Yashiro, M. Iguchi, H. Tamai, Y. Kameyama, J. Kato, N. Kondoh, M. Ichinose, Altered cytokine levels and increased CD4+CD57+ T cells in the peripheral blood of hepatitis C virus-related hepatocellular carcinoma patients, Oncol. Rep. 2011, 26, 201-208
176. M. Vistnes, A. Waehre, S. Nygard, I. Sjaastad, K. B. Andersson, C. Husberg, G. Christensen, Circulating cytokine levels in mice with heart failure are etiology dependent, J. Appl. Physiol. 2010, 108, 1357-1364
177. H. Tashiro, H. Shimokawa, K. Yamamoto, M. Momohara, H. Tada, A. Takeshita, Altered plasma levels of cytokines in patients with ischemic heart disease, Coron. Artery Dis. 1997, 8, 143-147
178. A. R. Murray, E. Kisin, A. Inman, S. H. Young, M. Muhammed, T. Burks, A. Uheida, A. Tkach, M. Waltz, V. Castranova, B. Fadeel, V. E. Kagan, J. E. Riviere, N. Monteiro-Riviere, A. A. Shvedova, Oxidative stress and dermal toxicity of iron oxide nanoparticles in vitro, Cell Biochem. Biophys. DOI: 10.1007/s12013-12012-19367-12019
179. W. S. Cho, R. Duffin, C. A. Poland, A. Duschl, G. J. Oostingh, W. Macnee, M. Bradley, I. L. Megson, K. Donaldson, Differential pro-inflammatory effects of metal oxide nanoparticles and their soluble ions in vitro and in vivo; zinc and copper nanoparticles, but not their ions, recruit eosinophils to the lungs, Nanotoxicology, 2012, 6, 22-35
180. S. Gui, Z. Zhang, L. Zheng, Y. Cui, X. Liu, N. Li, X. Sang, Q. Sun, G. Gao, Z. Cheng, J. Cheng, L. Wang, M. Tang, F. Hong, Molecular mechanism of kidney injury of mice caused by exposure to titanium dioxide nanoparticles, J. Hazard. Mater. 2011, 195, 365-370
181. Characterization of nanoparticles intended for drug delivery, ed. S. E. McNeil, Human Press, New York, 2011
182. S. Arora, J. M. Rajwade, K. M. Paknikar, Nanotoxicology and in vitro studies: the need of the hour, Toxicol. Appl. Pharmacol. 2012, 258, 151-165
183. V. Stone, H. Johnston, R. P. Schins, Development of in vitro systems for nanotoxicology: methodological considerations, Crit. Rev. Toxicol. 2009, 39, 613-626
184. A. Kroll, M. H. Pillukat, D. Hahn, J. Schnekenburger, Current in vitro methods in nanoparticle risk assessment: limitations and challenges, Eur. J. Pharm. Biopharm. 2009, 72, 370-377
185. B. J. Marquis, S. A. Love, K. L. Braun, C. L. Haynes, Analytical methods to assess nanoparticle toxicity, Analyst, 2009, 134, 425-439
186. M. A. Kutzler, D. B. Weiner, DNA vaccines: ready for prime time?, Nat. Rev. Genet. 2008, 9, 776-788
187. D. M. Mahvi, M. B. Henry, M. R. Albertini, S. Weber, K. Meredith, H. Schalch, A. Rakhmilevich, J. Hank, P. Sondel, Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial, Cancer Gene Ther. 2007, 14, 717-723
188. P. Chapman, C. Reyes, V. Gupta, Normal Physiological Levels of Human Cytokines Using Bio-Plex Pro™Cytokine Assays, Bio-Rad Tech Note, 2010, 6029
189. S. X. Leng, J. E. McElhaney, J. D. Walston, D. Xie, N. S. Fedarko, G. A. Kuchel, ELISA and multiplex technologies for cytokine measurement in inflammation and aging research, J. Gerontol. Ser. A, 2008, 63, 879-884
190. M. F. Elshal, J. P. McCoy, Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA, Methods, 2006, 38, 317-323
191. O. K. Bernhard, R. A. Mathias, T. W. Barnes, R. J. Simpson, A fluorescent microsphere-based method for assay of multiple analytes in plasma, Methods Mol. Biol. 2011, 728, 195-206
192. C. Munoz, B. Misset, C. Fitting, J. P. Bleriot, J. Carlet, J. M. Cavaillon, Dissociation between plasma and monocyte-associated cytokines during sepsis, Eur. J. Immunol. 1991, 21, 2177-2184
193. B. A. Beutler, I. W. Milsark, A. Cerami, Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo, J. Immunol. 1985, 135, 3972-3977
194. A. Sood, S. Salih, D. Roh, L. Lacharme-Lora, M. Parry, B. Hardiman, R. Keehan, R. Grummer, E. Winterhager, P. J. Gokhale, P. W. Andrews, C. Abbott, K. Forbes, M. Westwood, J. D. Aplin, E. Ingham, I. Papageorgiou, M. Berry, J. Liu, A. D. Dick, R. J. Garland, N. Williams, R. Singh, A. K. Simon, M. Lewis, J. Ham, L. Roger, D. M. Baird, L. A. Crompton, M. A. Caldwell, H. Swalwell, M. Birch-Machin, G. Lopez-Castejon, A. Randall, H. Lin, M. S. Suleiman, W. H. Evans, R. Newson, C. P. Case, Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness, Nat. Nanotechnol. 2011, 6, 824-833
195. A. Kocbach, A. I. Totlandsdal, M. Lag, M. Refsnes, P. E. Schwarze, Differential binding of cytokines to environmentally relevant particles: a possible source for misinterpretation of in vitro results?, Toxicol. Lett. 2008, 176, 131-137
196. J. M. Veranth, E. G. Kaser, M. M. Veranth, M. Koch, G. S. Yost, Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dusts, Part. Fibre Toxicol. 2007, 4, 2
197. Y. M. Thasneem, S. Sajeesh, C. P. Sharma, Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles, J. Biomed. Mater. Res. Part A, 2011, 99, 607-617
198. G. Sun, A. Hagooly, J. Xu, A. M. Nystrom, Z. Li, R. Rossin, D. A. Moore, K. L. Wooley, M. J. Welch, Facile, efficient approach to accomplish tunable chemistries and variable biodistributions for shell cross-linked nanoparticles, Biomacromolecules, 2008, 9, 1997-2006
199. K. Fukukawa, R. Rossin, A. Hagooly, E. D. Pressly, J. N. Hunt, B. W. Messmore, K. L. Wooley, M. J. Welch, C. J. Hawker, Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications, Biomacromolecules, 2008, 9, 1329-1339
200. E. D. Pressly, R. Rossin, A. Hagooly, K. Fukukawa, B. W. Messmore, M. J. Welch, K. L. Wooley, M. S. Lamm, R. A. Hule, D. J. Pochan, C. J. Hawker, Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers, Biomacromolecules, 2007, 8, 3126-3134
201. S. Chono, S. D. Li, C. C. Conwell, L. Huang, An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor, J. Controlled Release, 2008, 131, 64-69
202. S. D. Li, S. Chono, L. Huang, Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA, Mol. Ther. 2008, 16, 942-946
203. J. Li, Y. C. Chen, Y. C. Tseng, S. Mozumdar, L. Huang, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery, J. Controlled Release, 2010, 142, 416-421
204. J. K. Watts, G. F. Deleavey, M. J. Damha, Chemically modified siRNA: tools and applications, Drug Discovery Today, 2008, 13, 842-855